Clinical trials: Diabetic Maculopathy
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular…
- Trial name
- ELARA (NCT06491914)
- Testing
- Aflibercept 8 mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 1,126 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Macular Edema
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
- Trial name
- NCT02121262
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 18 sites in China, Philippines
- Volunteers
- 284 people
- Sponsor
- Allergan
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Macular Edema, Diabetic Mellitus
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.
- Conditions
- Macular Edema, Diabetic Mellitus, Retinal Disease
- Trial name
- NCT01100307
- Testing
- pegaptanib sodium
- Where
- 43 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Pfizer
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in…
- Trial name
- RESPOND (NCT01135914)
- Testing
- ranibizumab, Laser
- Where
- 20 sites in Canada
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
- Trial name
- NCT00782717
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, Prednisolone acetate ophthalmic suspension (OMNIPRED)
- Volunteers
- 263 people
- Sponsor
- Alcon Research
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan